Alanna Joyce Church, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
High-Throughput Nucleotide Sequencing | 11 | 2024 | 3618 | 1.160 |
Why?
|
Sarcoma | 6 | 2024 | 1786 | 1.080 |
Why?
|
Soft Tissue Neoplasms | 4 | 2022 | 1151 | 0.980 |
Why?
|
Pathology, Molecular | 2 | 2022 | 330 | 0.810 |
Why?
|
Neoplasms | 12 | 2024 | 22066 | 0.810 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2021 | 42 | 0.760 |
Why?
|
Genetics, Medical | 1 | 2024 | 336 | 0.750 |
Why?
|
Sarcoma, Clear Cell | 1 | 2021 | 72 | 0.740 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2022 | 70 | 0.740 |
Why?
|
Tandem Repeat Sequences | 1 | 2021 | 181 | 0.720 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 2 | 2023 | 184 | 0.690 |
Why?
|
Bone Neoplasms | 3 | 2023 | 2532 | 0.680 |
Why?
|
Nevus, Pigmented | 1 | 2022 | 221 | 0.680 |
Why?
|
Myofibroma | 1 | 2019 | 45 | 0.670 |
Why?
|
Fibrosarcoma | 2 | 2020 | 308 | 0.670 |
Why?
|
Fasciitis | 1 | 2019 | 66 | 0.640 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2024 | 1591 | 0.630 |
Why?
|
Osteosarcoma | 2 | 2023 | 898 | 0.620 |
Why?
|
Ribonuclease III | 1 | 2020 | 279 | 0.600 |
Why?
|
Nephroma, Mesoblastic | 1 | 2017 | 24 | 0.600 |
Why?
|
Resource Allocation | 1 | 2020 | 349 | 0.600 |
Why?
|
Parotid Neoplasms | 1 | 2019 | 157 | 0.600 |
Why?
|
Sequence Analysis, RNA | 5 | 2021 | 2003 | 0.590 |
Why?
|
DEAD-box RNA Helicases | 1 | 2020 | 383 | 0.570 |
Why?
|
Scalp | 1 | 2019 | 389 | 0.550 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2019 | 454 | 0.540 |
Why?
|
Specimen Handling | 2 | 2021 | 708 | 0.540 |
Why?
|
Proto-Oncogene Proteins | 4 | 2022 | 4494 | 0.510 |
Why?
|
Skull | 1 | 2019 | 815 | 0.490 |
Why?
|
Child | 34 | 2024 | 79758 | 0.470 |
Why?
|
Kidney Neoplasms | 3 | 2021 | 4312 | 0.470 |
Why?
|
Microtubule-Associated Proteins | 2 | 2022 | 1078 | 0.440 |
Why?
|
Myofibromatosis | 2 | 2023 | 27 | 0.430 |
Why?
|
Repressor Proteins | 2 | 2021 | 2978 | 0.420 |
Why?
|
Genomics | 10 | 2024 | 5790 | 0.420 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 1021 | 0.410 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 917 | 0.390 |
Why?
|
Gene Fusion | 4 | 2022 | 354 | 0.380 |
Why?
|
Adenomatous Polyposis Coli | 2 | 2023 | 218 | 0.370 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1899 | 0.330 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2024 | 2500 | 0.320 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3448 | 0.290 |
Why?
|
Child, Preschool | 13 | 2024 | 42034 | 0.280 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2024 | 556 | 0.270 |
Why?
|
Skin Neoplasms | 2 | 2023 | 5797 | 0.260 |
Why?
|
Infant | 12 | 2024 | 36030 | 0.260 |
Why?
|
Brain Neoplasms | 3 | 2022 | 8984 | 0.250 |
Why?
|
Dextromethorphan | 1 | 2005 | 37 | 0.250 |
Why?
|
Molecular Targeted Therapy | 4 | 2024 | 2805 | 0.240 |
Why?
|
Dizocilpine Maleate | 1 | 2005 | 172 | 0.240 |
Why?
|
Biomedical Research | 1 | 2020 | 3421 | 0.240 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2024 | 43 | 0.240 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2022 | 2415 | 0.230 |
Why?
|
Hypoxia, Brain | 1 | 2005 | 138 | 0.230 |
Why?
|
Adolescent | 17 | 2024 | 87747 | 0.230 |
Why?
|
Chromosome Aberrations | 2 | 2024 | 1767 | 0.220 |
Why?
|
Lymphangioma | 1 | 2023 | 61 | 0.220 |
Why?
|
Melanoma | 1 | 2022 | 5695 | 0.220 |
Why?
|
Myxoma | 1 | 2023 | 114 | 0.210 |
Why?
|
Medical Oncology | 2 | 2024 | 2321 | 0.200 |
Why?
|
Humans | 52 | 2024 | 760261 | 0.200 |
Why?
|
Fibromatosis, Aggressive | 1 | 2023 | 125 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2021 | 9274 | 0.200 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2024 | 317 | 0.200 |
Why?
|
Glomus Tumor | 1 | 2022 | 62 | 0.200 |
Why?
|
Granuloma, Plasma Cell | 1 | 2022 | 80 | 0.190 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2021 | 67 | 0.190 |
Why?
|
Receptor, trkA | 1 | 2022 | 159 | 0.190 |
Why?
|
Neocortex | 1 | 2005 | 416 | 0.190 |
Why?
|
Chromosomes | 1 | 2024 | 575 | 0.180 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2024 | 2297 | 0.180 |
Why?
|
Laboratories | 1 | 2024 | 461 | 0.180 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2021 | 114 | 0.170 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.170 |
Why?
|
Biopsy | 3 | 2020 | 6775 | 0.170 |
Why?
|
DNA Copy Number Variations | 2 | 2019 | 2008 | 0.170 |
Why?
|
Tissue Banks | 1 | 2020 | 185 | 0.170 |
Why?
|
Codon | 1 | 2021 | 602 | 0.170 |
Why?
|
Immunophenotyping | 1 | 2024 | 1870 | 0.160 |
Why?
|
Oncogenes | 2 | 2022 | 1221 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 115 | 0.160 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2020 | 612 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2020 | 225 | 0.150 |
Why?
|
Neuroprotective Agents | 1 | 2005 | 961 | 0.150 |
Why?
|
Carcinoma | 2 | 2021 | 2334 | 0.150 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2022 | 619 | 0.150 |
Why?
|
Thyroid Diseases | 1 | 2021 | 386 | 0.150 |
Why?
|
Lymphoma, T-Cell | 1 | 2020 | 305 | 0.150 |
Why?
|
Young Adult | 7 | 2024 | 58673 | 0.150 |
Why?
|
Immunohistochemistry | 3 | 2020 | 11064 | 0.150 |
Why?
|
Thyroid Neoplasms | 2 | 2022 | 2332 | 0.140 |
Why?
|
Spleen | 1 | 2023 | 2298 | 0.140 |
Why?
|
Lymphatic Diseases | 1 | 2018 | 319 | 0.140 |
Why?
|
Liver Neoplasms | 2 | 2024 | 4317 | 0.140 |
Why?
|
Mutation | 11 | 2024 | 29950 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2017 | 311 | 0.140 |
Why?
|
Receptor, IGF Type 1 | 1 | 2018 | 380 | 0.130 |
Why?
|
Necrosis | 1 | 2020 | 1612 | 0.130 |
Why?
|
Male | 24 | 2024 | 359413 | 0.130 |
Why?
|
Piperazines | 2 | 2016 | 2520 | 0.130 |
Why?
|
Neuroblastoma | 1 | 2024 | 1252 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1132 | 0.130 |
Why?
|
Sexual Development | 1 | 2015 | 40 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 346 | 0.130 |
Why?
|
Karyopherins | 1 | 2016 | 130 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 346 | 0.130 |
Why?
|
GTP Phosphohydrolases | 1 | 2018 | 516 | 0.130 |
Why?
|
Exons | 1 | 2021 | 2391 | 0.130 |
Why?
|
Rare Diseases | 2 | 2021 | 619 | 0.120 |
Why?
|
Female | 23 | 2024 | 391011 | 0.120 |
Why?
|
Thyroid Nodule | 1 | 2022 | 760 | 0.120 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2015 | 430 | 0.120 |
Why?
|
Adult | 11 | 2024 | 219847 | 0.110 |
Why?
|
Teratoma | 1 | 2015 | 403 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1118 | 0.100 |
Why?
|
Adenoma | 1 | 2023 | 2148 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1314 | 0.100 |
Why?
|
Infant, Newborn | 3 | 2024 | 26168 | 0.100 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 854 | 0.100 |
Why?
|
Cell Proliferation | 2 | 2024 | 10434 | 0.100 |
Why?
|
Recombinant Fusion Proteins | 1 | 2019 | 3735 | 0.090 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2013 | 237 | 0.090 |
Why?
|
Prognosis | 5 | 2023 | 29636 | 0.090 |
Why?
|
Testicular Neoplasms | 1 | 2015 | 800 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2359 | 0.080 |
Why?
|
Genetic Testing | 2 | 2021 | 3530 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4637 | 0.080 |
Why?
|
Curriculum | 1 | 2021 | 3722 | 0.070 |
Why?
|
Glioma | 1 | 2022 | 3420 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 17766 | 0.070 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 16905 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 6030 | 0.070 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 1892 | 0.070 |
Why?
|
Lymphoma, B-Cell | 1 | 2013 | 935 | 0.070 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6310 | 0.060 |
Why?
|
Cytoskeletal Proteins | 2 | 2022 | 1344 | 0.060 |
Why?
|
Receptors, sigma | 1 | 2005 | 45 | 0.060 |
Why?
|
Neoplasm Transplantation | 2 | 2019 | 2014 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3584 | 0.050 |
Why?
|
Scattering, Radiation | 1 | 2005 | 488 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20048 | 0.050 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2022 | 40 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10183 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 54263 | 0.050 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2023 | 180 | 0.050 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 12 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2018 | 7854 | 0.050 |
Why?
|
Mice, Nude | 2 | 2019 | 3605 | 0.050 |
Why?
|
Cortical Spreading Depression | 1 | 2005 | 288 | 0.050 |
Why?
|
Lip | 1 | 2022 | 197 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 8498 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5640 | 0.050 |
Why?
|
Oncogene Fusion | 1 | 2020 | 81 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13249 | 0.040 |
Why?
|
Cell Cycle | 2 | 2019 | 2937 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2022 | 495 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 635 | 0.040 |
Why?
|
RNA Interference | 2 | 2019 | 2846 | 0.040 |
Why?
|
Light | 1 | 2005 | 1344 | 0.040 |
Why?
|
United States | 2 | 2024 | 72363 | 0.040 |
Why?
|
Karyotyping | 1 | 2020 | 1172 | 0.040 |
Why?
|
Calcitonin | 1 | 2019 | 330 | 0.040 |
Why?
|
Gene Amplification | 1 | 2023 | 1085 | 0.040 |
Why?
|
beta Catenin | 1 | 2023 | 1043 | 0.040 |
Why?
|
Carbazoles | 1 | 2019 | 221 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 345 | 0.040 |
Why?
|
Ligands | 1 | 2005 | 3277 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4891 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3784 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4717 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 473 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 80301 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2020 | 1122 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2021 | 1115 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1614 | 0.030 |
Why?
|
Hydrazines | 1 | 2016 | 224 | 0.030 |
Why?
|
Drug Synergism | 1 | 2018 | 1755 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2024 | 2874 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 840 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2641 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 717 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2005 | 8157 | 0.030 |
Why?
|
Orchiectomy | 1 | 2015 | 470 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 734 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1218 | 0.030 |
Why?
|
Mice | 4 | 2024 | 81216 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2017 | 58947 | 0.030 |
Why?
|
Paraffin Embedding | 1 | 2013 | 302 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2021 | 2143 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2024 | 3613 | 0.020 |
Why?
|
Animals | 5 | 2024 | 167940 | 0.020 |
Why?
|
Base Sequence | 1 | 2022 | 12447 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2022 | 2895 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18415 | 0.020 |
Why?
|
Piperidines | 1 | 2019 | 1650 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 904 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2023 | 3537 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21065 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2017 | 1739 | 0.020 |
Why?
|
Doxorubicin | 1 | 2016 | 2207 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2024 | 11141 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 6067 | 0.020 |
Why?
|
Rats | 1 | 2005 | 23695 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1843 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8058 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9388 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4109 | 0.020 |
Why?
|
Ultrasonography | 1 | 2021 | 5960 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6900 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13629 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11708 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12968 | 0.020 |
Why?
|
Middle Aged | 2 | 2017 | 220175 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2024 | 64947 | 0.020 |
Why?
|
Aged | 1 | 2017 | 168995 | 0.020 |
Why?
|
Pyridines | 1 | 2016 | 2877 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15273 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5333 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13505 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15687 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5230 | 0.010 |
Why?
|
Genetic Variation | 1 | 2018 | 6540 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7072 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9590 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8805 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16543 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10757 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25928 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7592 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10185 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39254 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41317 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 15766 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6855 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23363 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 74269 | 0.010 |
Why?
|